Insmed reports second-quarter 2025 financial results and provides business update

—arikayce® (amikacin liposome inhalation suspension) total revenue of $107.4 million for the second quarter of 2025, reflecting 19% growth over the second quarter of 2024— —nda for brensocatib in patients with bronchiectasis remains on track, with a pdufa target action date of august 12, 2025— —tpip program advancing with phase 3 studies planned to begin for ph-ild in the second half of 2025 and for pah in early 2026— —topline data anticipated for phase 2b birch study of brensocatib in patients with crssnp by the end of 2025— —company reiterates 2025 global arikayce revenue guidance range of $405 million to $425 million, reflecting double-digit growth compared to 2024— bridgewater, n.j. , aug. 7, 2025 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the second quarter ended june 30, 2025 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking